Market accessOfficial

Commission publishes joint clinical assessment report on camizestrant for breast cancer

🇪🇺 European Commission (DG SANTE) · Fri 06 Nov 2026

The report on camizestrant (Etcamah), prepared by Austria and Belgium under the EU HTA Regulation, will feed into national decision-making by Member States.

The European Commission has published a joint clinical assessment (JCA) report on camizestrant, marketed as Etcamah, a medicine for treating breast cancer. The announcement appeared in the newsletter of its health and food safety directorate-general on 6 November 2026.

The assessment was carried out by the competent authorities of Austria and Belgium under the EU Health Technology Assessment (HTA) Regulation. Member States endorsed the report on 19 August 2026. The Commission had granted marketing authorisation for the product on 20 July 2026.

According to the Commission, joint clinical assessments let Member States work together to evaluate the clinical benefits of new medicines, and certain medical devices, against existing health technologies. Patients and clinical experts are consulted systematically during the process. The outcome is a JCA report and a summary report, which Member States will use in their national decision-making procedures.

The Commission said further JCA reports will be published in the coming months on its HTA website. It also maintains a JCA tracker table, updated regularly, listing the assessments currently under way. The newsletter item does not describe the report's findings.

What it means for your team

  • Market-access teams handling camizestrant in the EU should obtain the JCA report and summary report from the Commission's HTA website, as Member States will use them nationally.
  • The report was endorsed in August 2026, after the July 2026 marketing authorisation, so this entry marks a completed step in the process rather than a new assessment.
  • Teams tracking other pipeline products can follow the Commission's JCA tracker table for ongoing assessments and for further reports due in coming months.

Official source: European Commission (DG SANTE) ↗

Article written by VigiEye from the official source (European Commission (DG SANTE)). AI-assisted; check the source before acting.

More Market access All →